RIKEN <A HREF="https://mus.brc.riken.jp/en/mouse_of_month/feb_2007_mm" target="_blank">Mouse of the Month Feb 2007</A><br><a href="https://mus.brc.riken.jp/ja/wp-content/uploads/pdf/blc/01834_GB.pdf">Genetic Background</a> 糸原　重美 条件を付加する。<br>研究成果の公表にあたって寄託者の指定する文献を引用する。Experimental Animals, 55, 137-141 (2006). C57BL/6-Tg(CAG-flpe)36Ito/ItoRbrc C57BL/6-Tg(CAG-flpe)36Ito/ItoRbrc Carrier x Noncarrier [C57BL/6JJcl] Carrier x Noncarrier [C57BL/6JJcl] 理化学研究所脳科学総合研究センター・神吉浩明先生、糸原重美先生（2006）。C57BL/6受精卵へTgのインジェクションにより作出。C57BL/6J背景。 独立行政法人理化学研究所 This transgenic mouse of C57BL/6 strain expresses the FLPe recombinase under the control of the CAG promoter. FLPe is a variant of the FLP recombinase with a higher enzymatic activity at 37 degrees C. The FLP-FRT system is similar to the cre-loxP system and is useful for more complex dual approaches that combine FLP with other recombinases, such as Cre and phi C31. This strain can be used to make an inducible knock-out by crossing with the other genetically-engineered mice that have a pair of FLP recombinase target (FRT) sequence flanking the genomic region of interest. Deposited by Hiroaki Kanki and Shigeyoshi Itohara, RIKEN Brain Science Institute in 2006. The transgene was injected into the pronuclei of C57BL/6 fertilized eggs. C57BL/6J background. RBRC01834 true B (1-3 months) CAG promoter (CMV-IE enhancer, chicken beta-actin promoter, rabbit beta-globin genomic DNA), yeast FLPe cDNA, Encephalomyocarditis virus (EMCV) internal ribosomal entry site (IRES), Streptomyces alboniger puromycin resistance gene CAGプロモーター制御下でFLPeを発現するトランスジェニックマウス。 In publishing the research results obtained by use of the BIOLOGICAL RESOURCE, a citation of the following literature(s) designated by the DEPOSITOR is requested. Experimental Animals, 55, 137-141 (2006). Necessary documents for ordering:<ol><li>Order form (<A HREF="https://mus.brc.riken.jp/ja/wp-content/uploads/form/form_4.docx">Japanese</A> / <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_b.docx">English</A>)</li><li>Category I MTA: MTA for distribution with RIKEN BRC (<A HREF="https://mus.brc.riken.jp/ja/wp-content/uploads/form/form_5.docx">Japanese</A> / <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_c.docx">English</A>)</li><li>CAGGS MTA (<A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/CAGGS_MTA.docx">English</A>)</li><li>Acceptance of responsibility for living modified organism (<A HREF="https://mus.brc.riken.jp/ja/wp-content/uploads/form/form_7.docx">Japanese</A> / <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_g.docx">English</A>)</li></ol> <a href='https://brc.riken.jp/mus/pcr01834'>Genotyping protocol -PCR-</a> B（1〜3か月） FLP/frt system B6-Tg(CAG-FLPe)36; C57BL/6-Tg(CAG-FLPe)36Ito/ItoRbrc B6-Tg(CAG-FLPe)36; C57BL/6-Tg(CAG-FLPe)36Ito/ItoRbrc Genetics Research ShigeYoshi ITOHARA General Purpose